Warrigal
SF VIP
- Location
- Sydney, Australia
A company behind the pain killer known here a Nurofen is being sued over its policy of selling identical product in different coloured boxes and pretending that they are different.
The specific pain range is also sold for double the cost of the standard painkiller.
What is the situation in the US? Is this a common practice and do we all have to read the packets on non prescription drugs more carefully?
The specific pain range is also sold for double the cost of the standard painkiller.
JUST a reminder: no, the pink packet doesn’t actually target period pain.
Drug maker Reckitt Benckiser could be facing millions of dollars in fines for allegedly misleading consumers with its multicoloured Nurofen packs.
RB is being sued by the Australian Competition and Consumer Commission over claims that its four Nurofen Specific Pain products — Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain, and Nurofen Tension Headache — are each formulated to treat that specific kind of pain, when in fact the products are identical.
In documents filed with the Federal Court this morning, the ACCC alleges the conduct is misleading and deceptive, as the caplets in all four products contain the same active ingredient, ibuprofen lysine 342mg.
The Specific Pain range is sold for retail prices of around double that of Nurofen’s standard ibuprofen products and the standard products of its competitors. Chemist Warehouse, for example, sells a 24-pack of Nurofen Back Pain for $10.99, while a 24-pack of Nurofen 200mg sells for $4.69.
The ACCC alleges that RB made representations on the Nurofen packaging and on its website that each product: was designed and formulated to treat a particular type of pain; had specific efficacy in treating a particular type of pain; and solely treated a particular type of pain.
In fact, each of the four products is registered with the Australian Register of Therapeutic Goods with the same approved indication, covering a wide variety of pain types.
ACCC Chairman Rod Sims said the watchdog takes false or misleading claims about the efficacy of health and medical products very seriously, with truth in advertising and consumer issues in the sector flagged as key priorities for 2015.
What is the situation in the US? Is this a common practice and do we all have to read the packets on non prescription drugs more carefully?